Keros Therapeutics (NASDAQ:KROS) Downgraded to Market Perform Rating by William Blair

William Blair downgraded shares of Keros Therapeutics (NASDAQ:KROS) from an outperform rating to a market perform rating in a research report report published on Thursday, Marketbeat reports.

Several other brokerages have also issued reports on KROS. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Wells Fargo & Company increased their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Guggenheim restated a “buy” rating and issued a $102.00 price objective (up from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.22.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $18.43 on Thursday. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00. The company’s 50 day moving average is $59.95 and its two-hundred day moving average is $52.83.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.33) EPS. As a group, research analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in the stock. KBC Group NV increased its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the 3rd quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics in the 3rd quarter worth approximately $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.